Insider · CIK 0001759703
Matthew T. Wiley
Files at BTAIQ (BioXcel Therapeutics, Inc.), DFTX (Definium Therapeutics, Inc.). First filing Jun 26, 2026, latest Sep 29, 2026.
In brief
Matthew T. Wiley files SEC Form 4 as officer at DFTX (Definium Therapeutics, Inc.), and also at BTAIQ (BioXcel Therapeutics, Inc.). Since Jun 26, 2026, Matthew T. Wiley has reported 0 open-market buys worth $0 and 2 open-market sells worth $242k, the latest filed on Sep 29, 2026.
A track record needs three past buys with six months of prices behind them; Matthew T. Wiley has 0, so none is measured yet.
The newest scored trade: sold $113k of DFTX on Sep 25, 2026, filed Sep 29, 2026, scored 20 (weak), under a 10b5-1 plan. In the last 12 months: 0 buys worth $0 and 2 sells worth $242k.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
DFTX: Definium Therapeutics, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 20Weak | Definium Therapeutics, Inc. | $113k 3,097 shares | -1% | - | |
| 21Weak | Definium Therapeutics, Inc. | $129k 2,867 shares | -2% | +590% from low0% from high |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Sep 25, 2026 | DFTX DEFINIUM THERAPEUTICS, INC. | 3,097 0.00% of outstanding | $114k | Sep 25, 2026 | $121k |
| Jun 25, 2026 | DFTX DEFINIUM THERAPEUTICS, INC. | 2,867 0.00% of outstanding | $121k | Jun 25, 2026 | none |
Transactions
Every row this insider has filed, 7 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 25, 2026 | DFTX Definium Therapeutics, Inc. | SOpen-market sale Common Shares10b5-1 | -3,097 | $36.57 | $113k | 359,036 | 14 d ago |
| Sep 14, 2026 | DFTX Definium Therapeutics, Inc. | AGrant or award Common Shares | +125,000 | $0.00 | $0 | 362,133 | 29 d ago |
| Aug 12, 2026 | DFTX Definium Therapeutics, Inc. | AGrant or award Common Shares | +62,500 | $0.00 | $0 | 237,133 | Aug 12, 2026 |
| Jun 25, 2026 | DFTX Definium Therapeutics, Inc. | SOpen-market sale Common Shares10b5-1 | -2,867 | $45.03 | $129k | 174,633 | Jun 26, 2026 |
| Jun 22, 2026 | DFTX Definium Therapeutics, Inc. | AGrant or award Common Shares | +62,500 | $0.00 | $0 | 177,500 | Jun 22, 2026 |
| Feb 3, 2026 | DFTX Definium Therapeutics, Inc. | AGrant or award Common Shares | +115,000 | $0.00 | $0 | 115,000 | Feb 5, 2026 |
| Jul 22, 2024 | BTAIQ BioXcel Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +1,875 | $0.00 | $0 | 1,875 | Apr 1, 2025 |
Questions about Matthew T. Wiley
Answered from the filings on this page, as of the latest one.
Is Matthew T. Wiley buying or selling?
In the last 12 months Matthew T. Wiley reported 0 open-market buys worth $0 and 2 open-market sells worth $242k on SEC Form 4; the latest was sold $113k of DFTX on Sep 25, 2026. Grants, option exercises and tax withholding are not counted.
How did Matthew T. Wiley's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Matthew T. Wiley has 0.
Where does Matthew T. Wiley file Form 4?
Matthew T. Wiley has filed Form 4 at DFTX (Definium Therapeutics, Inc.) as Chief Commercial Officer; BTAIQ (BioXcel Therapeutics, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.